Ann: Notice of Annual General Meeting/Proxy Form, page-16

First 16 Last

Share
Profile

Follow
Ianwil

13,306 Posts.

944

31/10/23

01:29

Post #: 70627675
Share

Originally posted by kira1256 ↑

I have doubts on IMU's SP changing dramatically as I don't see any near term catalysts. There is this perception that some how big pharma will take over IMU, but in reality, IMU aren't even leading in the oncolytic virus space. There are numerous other companies in this field and some are even ahead of IMU. Have a look at the current competitors of IMU https://www.nature.com/articles/s41392-023-01407-6#Tab1. There are several drugs in phase 1 and 2, indicating that all of these virotherapies have demonstrated some efficacy in killing cancer cell lines and reducing tumor burden in xenograft models. So IMU's CF33 does not seem all that special.

In fact, there are a few clinical trial in progress and clinical trials completed presentations at the SITC on oncolytic therapies that are different to IMU but addressing the same market of solid tumors. For instance, there are two presentations on an oncolytic therapy called RP1, a drug developed by the same researcher that discovered the only oncolytic therapy to be FDA approved, T-Vec. Thinking that big pharama will make a bid or license IMU's platform over other available options might be a bit delusional.

The current cash on hand only covers the clinical trials in progress. What about the clinical trials after phase 1? IMU are likely to raise more money in the future and Hopper is going to get a sweet bonus for raising cash again. The remuneration highlights an eye watering $3.9 million in cash payment to the key management personals and that is not including non-cash bonuses. Including non-cash bonuses the total key management compensation is $7.36 million which equates to 2.5% of current market cap. Pay has increased but the share price as decreased.

Expand

I think this company is more about the top people making a lot of money from the hope of others. I have not seen any articles in the media about our drugs that cure cancer in mice. This could drag on long enough for the main people to retire very wealthy and the share holders will live on in hope, all they need to do is make an announcement every now and then with a wink wink this is great. I would love to be proven wrong

Last edited by Ianwil: 31/10/23

IMU Price at posting: 4.2¢ Sentiment: None Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

GTR

GTI extends uranium mineralisation at Lo Hema through development drilling

3 stocks with antimony news on Thursday

ASX Market Open: Local bourse to trade green | Thursday September 12

CHN

Chalice jumps on Putin nickel export ban threat – but then there's bad news

NEC

Nine Entertainment announces its CEO is stepping down – on an ex-divvy day

SS1

Sun Silver confirms high-grade extension theory at Maverick Springs with 79.6 g/t intercept

MTM

Forget gallium: MTM says it's extracted gold from e-waste

DXB

Dimerix begins recruiting young kidney disease patients in Mexico for Phase 3

CU6

Clarity progresses SECuRE trial with positive safety results

BRX

Belararox to grow copper footprint in Botswana with 4,286 square km tenure